Beam Therapeutics (BEAM) Stock Price
Beam Therapeutics Price
Revenue has compounded at 345.0% per year over the past 6 years to 139.74 M USD. Beam Therapeutics's net margin stands at -57.2%, up from -714.9% several years earlier. Analysts set a median price target of 56.50 USD, implying 128.1% above the current price. Of 23 analysts, 20 rate the stock a buy — an overall Buy consensus.
Beam Therapeutics stock price
Beam Therapeutics business model & stock analysis
Frequently asked questions about Beam Therapeutics
Beam Therapeutics Inc's business model revolves around developing and commercializing precision genetic medicines using its proprietary base editing technology platform. By leveraging CRISPR technology, Beam aims to correct errors at the molecular level by making precise changes to the DNA code, allowing for the treatment of a wide range of diseases. By focusing on a diverse pipeline of therapeutics across multiple disease areas, Beam Therapeutics Inc aims to transform the landscape of genetic medicine and provide innovative solutions for patients in need.
Beam Therapeutics Inc is primarily active in the biotechnology industry. As a leading biotechnology company, Beam Therapeutics focuses on developing precision genetic medicines using its proprietary base editing platform. By harnessing the power of CRISPR technology, Beam Therapeutics aims to address a wide range of diseases caused by genetic mutations. With its innovative approach, extensive research, and strategic partnerships, Beam Therapeutics is at the forefront of advancements in gene editing and therapeutic solutions.
The main competitors of Beam Therapeutics Inc in the market include Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics.
Beam Therapeutics Inc. is a biotechnology company that was founded in 2017. It specializes in developing precision genetic medicines using its proprietary base editing technology. This innovative technology allows for the precise and efficient alteration of individual base pairs within the genome. Beam Therapeutics aims to address a wide range of diseases, including genetic and rare diseases, as well as oncology indications. The company's mission is to create a new class of genetic medicines that offer long-lasting and potentially curative benefits for patients. With its dedicated focus on base editing, Beam Therapeutics is at the forefront of advancing the field of genetic medicine.
Beam Therapeutics Inc has achieved significant milestones since its inception. These include the successful completion of their initial public offering (IPO) in 2020, raising substantial funds to support ongoing research and development activities. The company has also made advancements in its proprietary base editing technology platform, which holds great potential for treating a wide range of genetic diseases. Furthermore, Beam Therapeutics has established strategic collaborations with renowned academic institutions and biopharmaceutical companies to expedite the development and commercialization of their innovative therapies. These achievements highlight the company's dedication to revolutionizing healthcare through precise, durable, and efficient genetic medicines.
Beam Therapeutics Inc is primarily present in the United States.
Beam Therapeutics Inc is a leading biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform. The company's values center around innovation, collaboration, and commitment to improving patient lives. Beam Therapeutics is dedicated to advancing the understanding and application of base editing technology to address genetic diseases with unmet medical needs. By harnessing the potential of DNA base editing, the company aims to deliver transformative therapies that can permanently correct genetic mutations at the source. Through its cutting-edge approach and dedication to patient-centric innovation, Beam Therapeutics Inc strives to make a significant impact in the field of genetic medicine.
Analysts currently set an average price target of 54.75 USD for the Beam Therapeutics stock (median: 56.50 USD), implying +117.0 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Beam Therapeutics stock: 20 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Beam Therapeutics to generate revenue of 51.24 M USD and earnings per share of -4.30 USD.
Converted at the current exchange rate, the Beam Therapeutics share trades at 22.12 EUR (24.77 USD).
The Beam Therapeutics share (BEAM) is listed on 1 stock exchanges, including: NASDAQ (BEAM).
Beam Therapeutics Inc is a leading company in the gene therapy industry, specializing in the development of advanced gene editing tools. The company is headquartered in Cambridge, Massachusetts and was founded in 2018. Its unique approach involves using precision gene editing to treat and cure genetic diseases and incurable conditions. Beam Therapeutics has established itself based on the revolutionary BEAM technology platform, which allows for the creation of gene editing tools with extremely high precision. BEAM stands for Base Editing by Advanced Machinery, and it is a type of gene editing that specifically alters individual building blocks in the genome instead of replacing the entire gene. This enables researchers at Beam Therapeutics to treat diseases in the genome with high precision and without size limitations. Beam Therapeutics Inc offers its technology platform in various business areas. The company's core area of focus is the development of the groundbreaking BEAM technology platform, which serves as the foundation for the development of a variety of gene correction tools. These tools enable researchers to target and treat diseases in the genome through precision gene editing. Additionally, Beam Therapeutics Inc also offers the development of gene therapies for specific diseases. For example, the company is working on editing gene sequences associated with cancer, sickle cell anemia, and beta-thalassemia. In collaboration with development partners, gene therapies are being developed and tested to determine the most effective treatment for these conditions. Another business area is the provision of services. Beam Therapeutics Inc offers technical services to its customers, such as genetic screenings. It is also possible to develop custom genome editing tools for research purposes or internal use. Beam Therapeutics Inc has a strong network of partnerships and has entered into agreements with various companies and institutions. The goal of these collaborations is to develop new gene therapies and conduct clinical trials. Furthermore, Beam Therapeutics Inc aims to connect researchers and scientists from around the world to advance developments in gene editing. In conclusion, Beam Therapeutics Inc specializes in the development and commercialization of precision gene editing tools and gene therapies for the treatment of genetic diseases and incurable conditions. The company operates in various business areas and offers unique and innovative solutions to researchers, developers, and customers through its BEAM technology platform.
The expected revenue of Beam Therapeutics is 51.24 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Beam Therapeutics is -451.58 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Beam Therapeutics is currently -5.76. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Beam Therapeutics stock.
The price-to-sales ratio (P/S) of Beam Therapeutics is currently 50.73. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Beam Therapeutics stock.
The Eulerpool Quality Score for Beam Therapeutics is 3/10.
The ISIN of Beam Therapeutics is US07373V1052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Beam Therapeutics is A2PY7P. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Beam Therapeutics is BEAM. The ticker symbol is used to trade Beam Therapeutics shares on the stock exchange.
Beam Therapeutics stock
Beam Therapeutics Peer Group
Beam Therapeutics Ticker
Beam Therapeutics FIGI
All fundamentals and in-depth analysis of Beam Therapeutics
Our stock analysis for Beam Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beam Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.